comparemela.com

Latest Breaking News On - Program of abstracts - Page 1 : comparemela.com

First participant imaged in Phase II SAR-Bombesin prostate cancer trial in the US

/PRNewswire/ Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products.

United statesNew south walesAlan taylorLuke nordquistGuggerm bombesinNational cancer instituteProgram of abstractsTechnology platformDrug administrationPrnewswire clarity pharmaceuticalsUrology cancer centerClarity pharmaceuticalsCancer statistics centerTherapeutic goods agency special access schemeGu research network in omahaAmerican cancer society

Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US

/PRNewswire/ Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products.

New south walesUnited statesAlan taylorAndrei iagaruGuggerm bombesinNational cancer instituteAmerican society of clinical oncologyProgram of abstractsTechnology platformDrug administrationPrnewswire clarity pharmaceuticalsClarity pharmaceuticalsCancer statistics centerTherapeutic goods administrationAmerican cancer societyBiochemical recurrence

vimarsana © 2020. All Rights Reserved.